BioCentury
ARTICLE | Company News

Avicenna Inc., Intracel Corp., KS Biomedix deal

June 25, 2001 7:00 AM UTC

KSB will acquire cancer and contract manufacturing play Avicenna for £41.9 million ($59 million) comprising £37.2 million in stock valued at £4.30 per share and £4.65 million in cash. Avicenna has two technologies for delivery of cytotoxic agents to tumor cells called TransMID and AviMAB. KSB said both technologies can be used to deliver its monoclonal antibodies (MAbs). The lead TransMID product, TransMID-107R, is ready to begin Phase III trials to treat recurrent inoperable glioma, and three other TransMIDs are in Phase I studies for other cancers. ...